Daiichi Sankyo Company (BUL:D4S) - Stock Price, News & Analysis

D4S Stock Overview

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide.

D4S fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	5/6
Financial Health	6/6
Dividends	4/6

Rewards

Earnings are forecast to grow 18.75% per year

Earnings grew by 83.8% over the past year

Risk Analysis

Unstable dividend track record

Daiichi Sankyo Company, Limited Competitors

Sopharma AD

BUL:SFA

лв997.0m

Chugai Pharmaceutical

TSE:4519

JP¥8.3t

Merck KGaA

XTRA:MRK

€64.8b

Zoetis

NYSE:ZTS

US$72.8b

Price History & Performance

Summary of all time highs, changes and price drops for Daiichi Sankyo Company
Historical stock prices
Current Share Price	JP¥31.62
52 Week High	JP¥0
52 Week Low	JP¥0
Beta	0.29
1 Month Change	7.26%
3 Month Change	14.05%
1 Year Change	1.61%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-2.33%

Recent updates

Shareholder Returns

	D4S	BG Pharmaceuticals	BG Market
7D	12.1%	1.4%	1.3%
1Y	1.6%	10.0%	17.2%

Return vs Industry: D4S underperformed the BG Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: D4S underperformed the BG Market which returned 16.7% over the past year.

Price Volatility

Is D4S's price volatile compared to industry and market?
D4S volatility
D4S Average Weekly Movement	5.3%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	3.9%
10% most volatile stocks in BG Market	9.2%
10% least volatile stocks in BG Market	2.4%

Stable Share Price: D4S has not had significant price volatility in the past 3 months.

Volatility Over Time: D4S's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1899	17,435	Sunao Manabe	www.daiichisankyo.com

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol.

Daiichi Sankyo Company, Limited Fundamentals Summary

How do Daiichi Sankyo Company's earnings and revenue compare to its market cap?
D4S fundamental statistics
Market cap	€61.10b
Earnings (TTM)	€1.19b
Revenue (TTM)	€9.51b

51.2x

P/E Ratio

6.4x

P/S Ratio

Is D4S overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
D4S income statement (TTM)
Revenue	JP¥1.60t
Cost of Revenue	JP¥415.32b
Gross Profit	JP¥1.19t
Other Expenses	JP¥985.64b
Earnings	JP¥200.73b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	104.68
Gross Margin	74.07%
Net Profit Margin	12.53%
Debt/Equity Ratio	6.0%

How did D4S perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

48%

Payout Ratio

D4S Stock Overview

Rewards

Risk Analysis

Daiichi Sankyo Company, Limited Competitors

BUL:SFA

лв997.0m

TSE:4519

JP¥8.3t

XTRA:MRK

€64.8b

NYSE:ZTS

US$72.8b

Price History & Performance

Recent News & Updates

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Now 20% undervalued

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Now 20% undervalued

Recent updates

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Now 20% undervalued

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Now 20% undervalued

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Third quarter 2024 earnings released: EPS: JP¥34.71 (vs JP¥14.81 in 3Q 2023)

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

New major risk - Earnings quality

Second quarter 2024 earnings released: EPS: JP¥20.86 (vs JP¥20.58 in 2Q 2023)

Astrazeneca and Daiichi Sankyo Announces Positive Results from the Pivotal Tropion-Breast01 Phase Iii Trial

Daiichi Sankyo and Astrazeneca’S Enhertu Demonstrated Clinically Meaningful Survival Across Multiple Her2 Expressing Advanced Solid Tumors in Destiny-Pantumor02 Phase 2 Trial

Daiichi Sankyo and Astrazeneca Announce Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Daiichi Sankyo and AstraZeneca Announce Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

European Union Recommends ENHERTU for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited and AstraZeneca PLC Announce Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Daiichi Sankyo Announces First Patient Dosed in a First-In-Human Phase 1/2 Trial Evaluating DS-3939 in Patients with Several Types of Advanced Solid Cancers

Daiichi Sankyo Company, Limited's ENHERTU Receives Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Daiichi Sankyo Company, Limited to Report Q2, 2024 Results on Oct 31, 2023

Daiichi Sankyo Company, Limited Announces Vanflyta® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

First quarter 2024 earnings released: EPS: JP¥29.74 (vs JP¥9.84 in 1Q 2023)

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo Company, Limited Announces FDA Approves VANFLYTA (Quizartinib) in Combination with Standard Cytarabine and Antibody Indication

Daiichi Sankyo Company, Limited to Report Q1, 2024 Results on Jul 31, 2023

Daiichi Sankyo Announces Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Now 21% undervalued after recent price drop

Shareholder Returns

Price Volatility

About the Company

Daiichi Sankyo Company, Limited Fundamentals Summary

51.2x

6.4x

Earnings & Revenue

Dividends

1.1%

48%